Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xalkori
Biotech
Turning Point posts data on Rozlytrek rival
Turning Point Therapeutics has posted early phase 2 data on ALK inhibitor repotrectinib that suggest it may pose a threat to Roche’s Rozlytrek.
Nick Paul Taylor
Aug 20, 2020 9:15am
Xcovery's Xalkori challenger shines in phase 3
Aug 8, 2020 7:00am
Ignyta NSCLC durability data set stage for Pfizer fight
Oct 18, 2017 9:26am
Pfizer’s son of Xalkori impresses in phase 2 NSCLC trial
Oct 16, 2017 9:55am
ROS1 cancer patients set out to create disease models
Aug 15, 2017 8:55am
Ariad finishes rolling NDA for lung cancer; wants sped-up review
Aug 30, 2016 8:53am
